MAPDA (Mothers for Awareness and Prevention of Drug Abuse)的动态

Breaking News: US company, Lykos Therapeutics, faces setback as FDA rejects bid to use MDMA capsules for treating PTSD. FDA requests additional Phase 3 trial for more data. CEO Amy Emerson expresses disappointment for those in need of new treatment options. Stay tuned for updates on this groundbreaking development in psychedelic therapy. #BreakingNews #UScompany #LykosTherapeutics #FDA #MDMA #PTSD #Phase3trial #CEOAmyEmerson #disappointment #newtreatmentoptions #groundbreakingdevelopment #psychedelictherapy #FDArejection #healthcare #mentalhealth #therapy #clinicaltrials #research #treatmentoptions #innovation #medication #FDAapproval #mentalhealthawareness #medicalresearch #UShealthcare

In a NPR article looking back on how the drug epidemic impacted the United States in 2023, it set off the alarms for our nation trending in the wrong direction: “For the first time in U.S. history, fatal overdoses peaked above 112,000 deaths, with young people and people of color among the hardest hit. Drug policy experts, and people living with addiction, say the magnitude of this calamity now eclipses every previous drug epidemic, from crack cocaine in the 1980s to the prescription opioid crisis of the 2000s. Public health experts say fentanyl, a synthetic opioid far more powerful than heroin, is responsible for the majority of drug deaths.” There is an unnerving link between opioid and street fentanyl addiction. Victims get hooked on opioids first and then desperately look for an alternative that’s cheaper and easier to come by. Many of these opioid addictions begin after surgery as folks try to find pain relief. This is where we come in to help combat the opioid and street fentanyl crisis. At this critical moment, medical professionals, policy makers and regular people are all looking for a safer, non opioid alternative for pain management after surgery. Our Solo-Dex Fascile cPNB catheter is the answer. With the Solo-Dex Fascile(R) cPNB catheter, we’ve introduced fast, simple, and reliable regional anesthesia that continuously blocks pain allowing for safe pain management after surgery WITHOUT opioids. Our sustained, targeted anesthesia provides you an easy transition to non-opioid pain management. This means you’re able to recover comfortably at home and not worry about taking addictive painkillers. This is the future of smarter, safer pain management. Ask your surgeon today if Solo-Dex is right for you. To learn more visit us at solo-dex.com. #medtech #manufacturing #medicaldesign #medicaldevices #medicalengineering #healthcare #healthtechnology #healthtech https://lnkd.in/gsd5dRxK

Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. https://lnkd.in/db--dm79 The Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States. by Vakaramoko (Karam) Diaby Shubhram Pandey Vassiki S. Dr. Reem Al-Mutairi, PhD. Yagyesh Kanoria Soma Nag found the total budget impact of Ari 2MRTU being adopted as an alternative maintenance monotherapy for treating eligible patients with schizophrenia from a hypothetical US health plan of 1 million members was estimated to be a saving of $26,998 over 3 years. This represented a per member per month saving of $0.001 and a per treated member per month saving of $0.11 The introduction of Ari 2MRTU as a maintenance treatment for adults with schizophrenia is expected to be cost neutral (with a modest saving) with respect to payer budgets in the United States. This merits consideration as is a potentially favorable option for patients who benefit from less frequent dosing. Otsuka Pharmaceutical Companies (U.S.) #HEOR #Middleast #market #pharma #marketaccess #ispor #ispo2024 #ICER #economics #healthcareconsulting #pharmacoeconomics #ispor #isporeurope #healtheconomics #EvidenceGeneration #EconomicsEvaluation #Modeling #Pricingandreimbursement #drreemalmutairi

Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD The timing of this report offers a welcome reprieve from the skepticism of groups across the pond like ICER and FDA’s PDAC. But whether it translates into meaningful action or, perhaps more pertinently, access, is yet to be seen. While its timing might have buoyed wavering sentiment among global MDMA-assisted therapy advocates, closer to home—in the Netherlands—its proximity to a transition of government might mire the saliency of its recommendations. (Despite the fact that Geert Wilders’ former spokesman quit after using party cash to buy drugs, the leader of the country’s largest party has touted a ‘drug-free Netherlands’ direction.) Still, given that the authors avoid recommending political hot potatoes like rescheduling and instead favour more stepwise measures such as a careful roll-out within the context of a naturalistic study, their prescriptions might just make it past the new government’s sniff test. It’s likely too early to speculate, but I can’t help but wonder what the commercial roll-out of MDMA-assisted therapy might look like in the Netherlands if it gains approval via the findings of a naturalistic study, or side-steps approval altogether and is accessible through some alternative route. Might we see generic MDMA come to market, in that scenario, totally dodging drug developers like Lykos in a move that would be more akin to Australia’s limited rescheduling of MDMA and psilocybin or Switzerland’s legal framework?

Is Australia on the brink of an opioid crisis? From the article: A colleague working in Northern Europe told Dr István Bitter, MD, PhD, DSc that the semisynthetic #opioid?#Oxycodone?was being used to treat people with chronic?back pain. But opioids would never be considered for this condition in Hungary, he said. Moreover, prior oxycodone use may play a role in the subsequent misuse of benzodiazepines prescribed in an outpatient setting, Bitter observed. In summary, long-term opioid use for chronic pain has no place in the treatment of patients with psychiatric comorbidity, said Schellekens. "On the other hand, you have people that have already escalated their opiates. And then you should not simply stop it, but write down a tapering plan and schedule, collaborate to get it done." Over prescribing opioids is something all too common in Workers Compensation and CTP. Why are we allowing / funding such treatments which are discouraged in other parts of the world because of known risks? Opioids in backpain is extremely common, so too overuse of benzodiazepine medications. As part of Independent Med Management services we provide tailored reduction and cessation plans to doctors nothing they are often unable to establish a clear plan for themselves. https://lnkd.in/gQ8m5QSa

Congratulations to Bristol Myers Squibb & Karuna Therapeutics on the FDA approval of COBENFY?(xanomeline and trospirum chloride) US HCP for the treatment of schizophrenia in adults. This groundbreaking medication represents a significant advancement in the field of mental health, being the first antipsychotic drug to target cholinergic receptors rather than dopamine receptors. This achievement marks an important milestone in the ongoing efforts to address the challenges of #schizophrenia and provides a valuable new option for #healthcare providers in managing this complex disorder. Well done to all those involved in bringing this innovative treatment to patients in need. https://lnkd.in/gR_GWnSY

In a Yale Medicine Article ‘Why Is Fentanyl Driving Overdose Deaths?’, it stated: “In 2022, according to provisional data from the Centers for Disease Control and Prevention (CDC), close to 83,000 people died from opioid overdoses in the United States, the majority from fentanyl and other highly potent synthetic substances.” There is an unnerving link between opioid and street fentanyl addiction. Victims get hooked on opioids first and then desperately look for an alternative that’s cheaper and easier to come by. Many of these opioid addictions begin after surgery as folks try to find pain relief. This is where we come in to help combat the opioid and street fentanyl crisis. At this critical moment, medical professionals, policy makers and regular people are all looking for a safer, non opioid alternative for pain management after surgery. Our Solo-Dex Fascile cPNB catheter is the answer. With the Solo-Dex Fascile(R) cPNB catheter, we’ve introduced fast, simple, and reliable regional anesthesia that continuously blocks pain allowing for safe pain management after surgery WITHOUT opioids. Our sustained, targeted anesthesia provides you an easy transition to non-opioid pain management. This means you’re able to recover comfortably at home and not worry about taking addictive painkillers. This is the future of smarter, safer pain management. Ask your surgeon today if Solo-Dex is right for you. To learn more visit us at solo-dex.com. https://lnkd.in/eAzDCZqy #medtech #manufacturing #medicaldesign #medicaldevices #medicalengineering #healthcare #healthtechnology #healthtech

https://lnkd.in/gmpvZtZW Identifying chronic pain risks early could be a game-changer in reducing opioid dependence. By recognizing the signs before pain becomes severe, doctors can implement alternative treatments and pain management strategies, helping to curb the need for opioid prescriptions. This proactive approach offers hope for a healthier, opioid-free future, empowering individuals to manage pain without the risks of addiction. Learn how early detection can be a crucial step toward better pain relief and overall well-being.

INNERBLOOM SPOTLIGHT: On January 30, 2025, the FDA approved Vertex pharmaceuticals’ non-opioid painkiller alternative for the treatment of moderate to severe acute pain-Journavx. “The approval marks a milestone after a long history of unsuccessful efforts to develop painkillers without the destructive dependency of opioids, which have caused a horrific epidemic in the U.S.”. The bigger opportunity will be to win FDA approval for the treatment of chronic pain, where the risk of addiction is even greater. InnerBloom Recovery Services, LLC Concierge, personalized addiction recovery coaching, sober companioning, safe transport, interventions, aftercare management & relapse prevention services #Vertexpharmaceuticals #journavx #pain #addiction #recovery